AC Immune (ACIU) Equity Average (2017 - 2025)
AC Immune (ACIU) has disclosed Equity Average for 9 consecutive years, with $92.2 million as the latest value for Q4 2025.
- Quarterly Equity Average fell 40.4% to $92.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $92.2 million through Dec 2025, down 40.4% year-over-year, with the annual reading at $92.2 million for FY2025, 40.4% down from the prior year.
- Equity Average for Q4 2025 was $92.2 million at AC Immune, down from $154.6 million in the prior quarter.
- The five-year high for Equity Average was $245.0 million in Q4 2021, with the low at $92.2 million in Q4 2025.
- Average Equity Average over 5 years is $176.7 million, with a median of $178.3 million recorded in 2023.
- The sharpest move saw Equity Average decreased 4.61% in 2021, then crashed 40.4% in 2025.
- Over 5 years, Equity Average stood at $245.0 million in 2021, then dropped by 12.85% to $213.5 million in 2022, then decreased by 16.51% to $178.3 million in 2023, then dropped by 13.26% to $154.6 million in 2024, then crashed by 40.4% to $92.2 million in 2025.
- According to Business Quant data, Equity Average over the past three periods came in at $92.2 million, $154.6 million, and $178.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.